Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma.

MLA

Borthakur, Gautam, et al. “Phase 1 Study to Evaluate Crenigacestat (LY3039478) in Combination with Dexamethasone in Patients with T‐cell Acute Lymphoblastic Leukemia and Lymphoma.” Cancer (0008543X), vol. 127, no. 3, Feb. 2021, pp. 372–80. EBSCOhost, https://doi.org/10.1002/cncr.33188.

APA

Borthakur, G., Martinelli, G., Raffoux, E., Chevallier, P., Chromik, J., Lithio, A., Smith, C. L., Yuen, E., Oakley, G. J., Benhadji, K. A., & DeAngelo, D. J. (2021). Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma. Cancer (0008543X), 127(3), 372–380. https://doi.org/10.1002/cncr.33188

Chicago

Borthakur, Gautam, Giovanni Martinelli, Emmanuel Raffoux, Patrice Chevallier, Jörg Chromik, Andrew Lithio, Claire L. Smith, et al. 2021. “Phase 1 Study to Evaluate Crenigacestat (LY3039478) in Combination with Dexamethasone in Patients with T‐cell Acute Lymphoblastic Leukemia and Lymphoma.” Cancer (0008543X) 127 (3): 372–80. doi:10.1002/cncr.33188.